The federal government has taken its first concrete regulatory step against a group of lab-made kratom-derived compounds. At Community Medical Services (CMS), we know that headlines like this one raise real, personal questions for people who use these products — questions about supply, withdrawal, and what to do next. Here’s a clear look at what changed, what didn’t, and how our team can help.
A Quick Recap: How We Got Here
Back on July 1, 2026, the Drug Enforcement Administration announced its intent to temporarily control four lab-derived compounds under the Controlled Substances Act: concentrated synthetic 7-hydroxymitragynine (7-OH), mitragynine pseudoindoxyl, MGM-15, and MGM-16. These substances have shown up in unregulated pills, gummies, powders, and shots sold at convenience stores and smoke shops nationwide, and they are chemically engineered to produce much stronger opioid-like effects than the kratom plant itself.
What Changed on August 26
The DEA has now finalized part of that plan. Mitragynine pseudoindoxyl, MGM-15, and MGM-16 were placed into Schedule I effective immediately upon publication in the Federal Register on August 26, 2026, with the designation running through August 26, 2028. These three substances do not occur naturally in the kratom plant — they’re byproducts of chemical processing.
Notably absent from this finalized order: concentrated synthetic 7-OH itself. That piece of the July proposal is still working through the rulemaking process. Public comments closed on September 10, 2026, and a separate final order covering 7-OH is expected afterward.
In other words, if you or someone you love has been using a concentrated 7-OH product, that specific substance has not yet been placed in Schedule I — but federal officials have signaled clearly that it’s next.
Natural Kratom Leaf Is Not What’s Being Targeted
It’s worth repeating, because the distinction gets lost easily: traditional, unprocessed kratom leaf — the kind that’s been used for generations in Southeast Asia — contains only trace, naturally occurring amounts of 7-OH. The DEA’s action is aimed at products that have been chemically boosted well past that natural level, generally above 0.050% 7-OH by dry weight or more than one milligram per serving. The FDA has echoed this same distinction in its own guidance, flagging concentrated synthetic 7-OH as an opioid-like risk while stopping short of targeting the raw plant.
That said, labeling in this market is inconsistent at best. A product marketed simply as “kratom” may still contain concentrated or synthetically enhanced 7-OH, so reading ingredient panels carefully matters more than ever.
Why This Isn’t Just a Legal Story
Retailers and distributors will need to sort out compliance timelines and inventory questions with legal counsel. But for the people actually using these products, the scheduling news raises a more personal set of concerns. Regulators have been direct about why concentrated synthetic 7-OH drew attention in the first place: it acts on the same opioid receptors as prescription painkillers and can lead to tolerance, physical dependence, and addiction with regular use.
That means a shift in legal status doesn’t erase a physical dependence that may have already developed. Whether a product disappears from shelves because of scheduling, a retailer pulls it voluntarily, or someone simply decides it’s time to stop, cutting off use abruptly can trigger real withdrawal — anxiety, muscle aches, sweating, insomnia, and cravings that closely resemble opioid withdrawal.
Common Questions We’re Hearing
Does this mean 7-OH products are illegal right now?
Only partially. As of August 26, 2026, mitragynine pseudoindoxyl, MGM-15, and MGM-16 are Schedule I controlled substances. Concentrated synthetic 7-OH itself has not yet been finalized into Schedule I; that determination is still pending. Until it is, it remains subject to whatever state and local rules already apply where you live.
I’ve been using a 7-OH product and I’m worried about withdrawal. What should I do?
Talk to a professional before you stop cold turkey, especially if you’ve been using regularly or in high amounts. Medications used to treat opioid use disorder — including buprenorphine, methadone, and naltrexone — can ease withdrawal and reduce cravings, and they’re available through CMS clinics without judgment.
Will natural kratom leaf be banned too?
That’s not the current target. DEA and FDA have both said their focus is on concentrated, chemically altered 7-OH products, not the traditional leaf at naturally occurring levels. Still, watch for future rulemaking, since this is an evolving area of federal policy.
What happens to stores still holding 7-OH inventory?
For the three compounds scheduled on August 26, unauthorized manufacturing, distribution, and sale are now prohibited under federal law. For 7-OH specifically, retailers should watch for the forthcoming final order and consult legal counsel about remaining stock in the meantime.
You Don’t Have to Navigate This Alone
At Community Medical Services, we’ve spent decades helping people work through opioid use disorder with medication, counseling, and peer support — delivered without judgment. If shifting regulations have you rethinking your 7-OH use, or if you’re already feeling early withdrawal symptoms, our team can talk through your options and build a plan around your goals and health history. Reach out to a CMS clinic near you to take the next step.
